Scarica l'app Stockscreener
1.21
3.42%
0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.17
Aprire:
$1.2
Volume 24 ore:
11,037
Relative Volume:
0.22
Capitalizzazione di mercato:
$14.00M
Reddito:
$996.00K
Utile/perdita netta:
$-6.09M
Rapporto P/E:
-2.283
EPS:
-0.53
Flusso di cassa netto:
$-9.76M
1 W Prestazione:
+7.08%
1M Prestazione:
-3.20%
6M Prestazione:
+9.01%
1 anno Prestazione:
-28.84%
Intervallo 1D:
$1.19
$1.23
Intervallo di 1 settimana:
$1.0901
$1.23
Portata 52W:
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Confronta TXMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.2096 | 14.00M | 996.00K | -6.09M | -9.76M | -0.53 |
|
RGC
Regencell Bioscience Holdings Ltd
|
19.20 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
157.68 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.06 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.02 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.66 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
Mayne Pharma Group Unit Seeks Over $11.5 Million in Damages in US Court Complaint Against TherapeuticsMD - marketscreener.com
Mayne Pharma Files Legal Complaint Against TherapeuticsMD - TipRanks
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com - Defense World
TherapeuticsMD Reports Improved Q1 2025 Results - TipRanks
TherapeuticsMD Announces First Quarter 2025 Financial Results | - GuruFocus
TherapeuticsMD: Q1 Earnings Snapshot - CT Insider
TherapeuticsMD Announces First Quarter 2025 Financial Results - BioSpace
TherapeuticsMD Inc Reports Q1 2025 Results: EPS at -$0.06, Revenue Reaches $393K - GuruFocus
TherapeuticsMD Reports Q1 2025 Financial Results - TipRanks
TherapeuticsMD Q1 Operating Expenses USD 1.264 Million - marketscreener.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD) - TheStreet
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - MarketScreener
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Therapeuticsmd Inc Azioni (TXMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
2.04%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):